Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
The New England Journal of Medicine|April 21, 2015
Pembrolizumab for the treatment of non-small-cell lung cancerEdward B Garon, Naiyer A Rizvi, Rina Hui, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2020
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung CancerShirish Gadgeel, Delvys Rodríguez-Abreu, Giovanna Speranza, et al.
The New England Journal of Medicine|February 9, 2022
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast CancerPeter Schmid, Javier Cortes, Rebecca Dent, et al.
The New England Journal of Medicine|April 17, 2018
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung CancerLeena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, et al.
The New England Journal of Medicine|September 9, 2017
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung CancerScott J Antonia, Augusto Villegas, Davey Daniel, et al.
Oncoimmunology|January 3, 2024
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignanciesChia-Chi Lin, Elena Garralda, Patrick Schöffski, et al.
Clinical Breast Cancer|November 13, 2020
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET TrialArlene Chan, Beverly Moy, Janine Mansi, et al.
Journal for Immunotherapy of Cancer|February 26, 2022
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignanciesPatrick Schöffski, Daniel S W Tan, Miguel Martín, et al.
The New England Journal of Medicine|October 4, 2018
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLCScott J Antonia, Augusto Villegas, Davey Daniel, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 7, 2025
Common inherited loss-of-function mutations in the innate sensor NOD2 contribute to exceptional immune response to cancer immunotherapyMegan B Barnet, Katherine J L Jackson, Etienne Masle-Farquhar, et al.
Pageof 9